Ibrutinib plus standard chemotherapy effective in younger patients with diffuse large B-cell lymphoma – News-Medical.Net

Younger patients with specific genetic subtypes of non-GCB DLBCL, called MCD and N1, had an exceptional response to the treatment combination.
New evidence suggests that adding the targeted therapy ibrutinib (Imbruvica) to a standard chemotherapy regimen…

Click here to view the original article.